MX2020012651A - Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion. - Google Patents

Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion.

Info

Publication number
MX2020012651A
MX2020012651A MX2020012651A MX2020012651A MX2020012651A MX 2020012651 A MX2020012651 A MX 2020012651A MX 2020012651 A MX2020012651 A MX 2020012651A MX 2020012651 A MX2020012651 A MX 2020012651A MX 2020012651 A MX2020012651 A MX 2020012651A
Authority
MX
Mexico
Prior art keywords
preparation
pyrazoloheteroaryl
hydrochloride
derivative
crystal form
Prior art date
Application number
MX2020012651A
Other languages
English (en)
Inventor
Likun Wang
Zhenxing Du
Xiaoli Cao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020012651A publication Critical patent/MX2020012651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a una forma de cristal de un clorhidrato de un derivado de pirazoloheteroarilo y a un método de preparación; en particular, la presente invención se refiere a las formas de cristal I y II de un diclorhidrato de un compuesto representado por la fórmula (I): (ver Fórmula) las formas de cristal A, B y C de un monoclorhidrato del compuesto representado por la fórmula (I), y un método de preparación de las mismas; las formas de cristal del compuesto representado por la fórmula (I) de la presente invención tienen buena estabilidad de cristal y pueden usarse mejor para tratamiento clínico.
MX2020012651A 2018-05-25 2019-05-24 Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion. MX2020012651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810512563 2018-05-25
PCT/CN2019/088250 WO2019223773A1 (zh) 2018-05-25 2019-05-24 一种吡唑并杂芳基类衍生物盐酸盐的晶型及制备方法

Publications (1)

Publication Number Publication Date
MX2020012651A true MX2020012651A (es) 2021-02-02

Family

ID=68615672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012651A MX2020012651A (es) 2018-05-25 2019-05-24 Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion.

Country Status (11)

Country Link
US (1) US20210188856A1 (es)
EP (1) EP3808745A4 (es)
JP (1) JP2021526520A (es)
KR (1) KR20210013624A (es)
CN (1) CN111819178B (es)
AU (1) AU2019272463A1 (es)
BR (1) BR112020023875A2 (es)
CA (1) CA3100873A1 (es)
MX (1) MX2020012651A (es)
TW (1) TWI704916B (es)
WO (1) WO2019223773A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1311499T3 (da) 2000-08-08 2006-08-07 Ortho Mcneil Pharm Inc Bicycliske forbindelser som H3-receptorligander
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
EP2217239A2 (en) * 2007-11-07 2010-08-18 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
KR20100125245A (ko) 2008-01-17 2010-11-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 아데닌 화합물의 제조 방법
ES2623794T3 (es) * 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
WO2011031965A1 (en) 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
IN2012DN02984A (es) * 2009-10-22 2015-07-31 Gilead Sciences Inc
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
ES2804101T3 (es) * 2014-04-22 2021-02-03 Hoffmann La Roche Compuestos de 4-amino-imidazoquinolina
WO2018095426A1 (zh) * 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
TW201900647A (zh) * 2017-05-18 2019-01-01 大陸商江蘇恒瑞醫藥股份有限公司 雜芳基并吡唑類衍生物、其製備方法及其在醫藥上的應用
WO2020063858A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途

Also Published As

Publication number Publication date
TW202002965A (zh) 2020-01-16
CN111819178A (zh) 2020-10-23
EP3808745A4 (en) 2022-03-09
BR112020023875A2 (pt) 2021-02-09
KR20210013624A (ko) 2021-02-04
EP3808745A1 (en) 2021-04-21
JP2021526520A (ja) 2021-10-07
AU2019272463A1 (en) 2021-01-07
CN111819178B (zh) 2022-04-12
CA3100873A1 (en) 2019-11-28
US20210188856A1 (en) 2021-06-24
TWI704916B (zh) 2020-09-21
WO2019223773A1 (zh) 2019-11-28

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2018010192A (es) Inhibidores de glucosidasa.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PH12017501326A1 (en) Tgf-� inhibitors
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2018010191A (es) Inhibidores de glucosidasa.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
SG10201804026WA (en) Inhibitors of influenza viruses replication
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
BR112019003320A2 (pt) compostos de heteroaril carboxamida como inibidores de ripk2
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
SG11201810725WA (en) Novel β-lactamase inhibitors
PH12019500822A1 (en) Crystalline forms of eravacycline
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
ZA202206266B (en) Pd-l1 antagonist compound
MY198008A (en) Crystal of benzofuran derivative free base and preparation method